rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: A new approach to attenuate liver fibrosis in rats

Hepatology

Volumn 42, Issue 2, 2005, Pages 335-342

  Tsui, Tung Yu ^a,b,d,e   Lau, Chi Keung ^a,b   Ma, Jian ^b   Wu, Xiaobing ^c   Wang, Yan Qing ^a,b   Farkas, Stefan ^d   Xu, Ruian ^a   Schlitt, Hans J ^d   Fan, Sheung Tat ^a,b  

^a Center Far the Study of Liver Disease   (Germany)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c CAPM   (China)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON TETRACHLORIDE; COLLAGEN TYPE 1; CYTOKINE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1ALPHA; HEME OXYGENASE 1; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; GENETIC TRANSDUCTION; IMMUNOCOMPETENT CELL; INFLAMMATION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTYPE; STELLATE CELL; TRANSGENE; VIRAL GENE THERAPY;

ANIMALS; CELL PROLIFERATION; COLLAGEN TYPE I; DEPENDOVIRUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEME OXYGENASE (DECYCLIZING); HEME OXYGENASE-1; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; RATS; RATS, INBRED LEW; RECEPTORS, VIRUS; TRANSGENES;

EID: 23044485967     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20803     Document Type: Article

References (41)

1. Friedman SL. The cellular basis of hepatic fibrosis-mechanisms and treatment strategies. N Engl J Med 1993;328:1828-1835.
2. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. HEPATOLOGY 2003;37:493-503.
3. Pelletier G, Roulot D, Davion T, Masliah C, Causse X, Oberti F, et al.; URSOMAF Group. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice. HEPATOLOGY 2003;37:887-892.
4. Cortez-Pinto H, Alexandrino P, Camilo ME, Gouveia-Oliveira A, Santos PM, Alves MM, et al. Lack of effect of olchicines in alcoholic cirrhosis: final results of a double blind randomized trial. Eur J Gastroenterol Hepatol 2002;14:377-381.
5. Lucena MI, Andrade RJ, de la Cruz JP, Rodriguez-Mendizabal M, Blanco E, Sanchez de la Cuesta F. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-lind, placebo-controlled clinical study. Int J Clin Pharmacol Ther 2002;40:2-8.
6. Gramenzi A, Andreone P, Fiorino S, Camma C, Giunta M, Magalotti D, et al. Impact of Interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001;48:843-848.
7. Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002;123:1044-1051.
8. Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. HEPATOLOGY 2001;33:22-27.
9. Platz KP, Mueller AR, Spree E, Schumacher G, Nussler NC, Rayes N, et al. Liver transplantation for alcoholic cirrhosis. Transpl Int 2000;13(Suppl 1):S127-S130.
10. Rockey DC, The cell and molecular biology of hepatic fibrogenesis: clinical and therapeutic implications. Clin Liver Dis 2000;4:319-355.
11. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997;37:517-554.
12. Schuller DJ, Wilks A, Ortiz de Montellano PR, Poulos TL. Crystal structure of human heme oxygenase-1. Nat Struct Biol 1999;6:860-867.
13. Goda N, Suzuki K, Naito M, Takeoka S, Tsuchida E, Ishimura Y, et al. Distribution of heme oxygenase isoforms in rat liver. Topographic basis for carbon monoxide-mediated microvascular relaxation. J Clin Invest 1998; 101:604-612.
14. Bauer I, Wanner GA, Rensing H, Alte C, Miescher EA, Wolf B, et al. Expression pattern of heme oxygenase isoenzymes 1 and 2 in normal and stress-exposed rat liver. HEPATOLOGY 1998;27:829-838.
15. Redaelli CA, Tian YH, Schaffner T, Ledermann M, Baer HU, Dufour JF. Extended preservation of rat liver graft by induction of heme oxygenase-1. HEPATOLOGY 2002;35:1082-1092.
16. Kato Y, Shimazu M, Kondo M, Uchida K, Kumamoto Y, Wakabayashi G, et al. Bilirubin rinse: a simple protectant against the rat liver graft injury mimicking heme oxygenase-1 preconditioning, HEPATOLOGY 2003;38:364-373.
17. Kyokane T, Norimizu S, Taniai H, Yamaguchi T, Takeoka S, Tsuchida E, et al. Carbon monoxide from heme catabolism protects against hepatobiliary dysfunction in endotoxin-treated rat liver, Gastroenterology 2001; 120: 1227-1240.
18. Ke B, Buelow R, Shen XD, Melinek J, Amersi F, Gao F, et al. Heme oxygenase 1 gene transfer prevents CD95/Fas ligand-mediated apoptosis and improves liver allograft survival via carbon monoxide signaling pathway. Hum Gene Ther 2002;13:1189-1199.
19. Tsui TY, Wu X, Lau CK, Ho DW, Xu T, Siu YT, et al. Prevention of chronic deterioration of heart allograft by recombinant adeno-associated virus-mediated heme oxygenase-1 gene transfer. Circulation 2003;107: 2623-2629.
20. Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000;105:74l-748.
21. Proctor E, Chatamra K. High yield micronodular cirrhosis in the rat. Gastroenterology 1982;83:1183-1190.
22. Bergman I, Loxley R. Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal Chem 1963;35: 1961-1965.
23. Summerford C, Samulski RJ. Membrane-associated heparin sulfate proteoglycan is a receptor for adeno-associated virus type 2 virons. J Virol 1998;72:1438-1445.
24. Summerford C, Bartlett J, Samulski RJ. αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999;5:78-82.
25. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999;5:71-77.
26. Fujimoto J, Kaneda Y. Reversing liver cirrhosis: impact of gene therapy for liver cirrhosis. Gene Ther 1999;6:305-306.
27. Monahan PE, Salmuski RJ. AAV vectors: is clinical success on the horizon? Gene Ther 2000;7:24-30.
28. Roskams T, Rosenbaum J, De Vos R, David G, Desmet V. Heparan sulfate proteoglycan expression in chronic cholestatic human liver diseases. HEPATOLOGY 1996;24:524-532.
29. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001;21:397-416.
30. Carloni V, Romanelli RG, Pinzani M, Laffi G, Gentilini P. Expression and function of integrin receptors for collagen and laminin in cultured human hepatic stellate cells. Gastroenterology 1996;110:1127-1136.
31. Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A, et al. The atomic structure of adeno-assoicated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A 2002;99:10405-10410.
32. Yang C, Zeisberg M, Mosterman B, Sudhakar A, Yerramalla U, Holthaus K, et al. Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology 2003;124:147-159.
33. Guo ZS, Wang LH, Eisensmith RC, Woo SCL. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther 1996;3:802-810.
34. Löser P, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFκB. J Virol 1998;72:180-190.
35. Miao CH, Nakai H, Thompson AR, Strom TA, Chiu W, Snyder RO, et al. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocyte in vivo: cell cycling does not influence hepatocyte trsnduction. J Virol 2000;74:3793-3803.
36. Thomas CE, Strom TA, Huang Z, Kay MA. Rapid uncoating of vector genome is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 2004;78:3110-3122.
37. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci U S A 1968; 61:748-755.
38. Braggins PE, Trakshel GM, Kutty RK, Maines MD. Characterization of two heme oxygenase isoforms in spleen: comparison with the hematin-induced and constitutive isoforms of the liver. Biochem Biophys Res Commun 1986;141:528-533.
39. Li L, Grenard P, Nhien JT, Julien B, Mallat A, Habib A, et al. Heme oxygeanse-1 is an anti-fibrogenic protein in human hepatic myofibrobalsts. Gastroenterology 2003;125:460-469.
40. Sass G, Soares MC, Yamashita K, Seyfried S, Zimmermann WH, Eschenhagen T, et al, Heme oxygenase-1 and its reaction product, carbon monoxide, prevent inflammation-related apoptotic liver damage in mice. HEPATOLOGY 2003;38:909-918.
41. Otterbein LE, Soares MP, Yamashita K, Bach FH. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol 2003;24: 449-455.